Biopharma AI
ByWhich AI Biopharma Startups Truly Won in 2025—And How Did NVIDIA, Big Pharma Collaborations, and Deal Value Define Success?
Executive Perspective 2025 marked a decisive shift for AI biopharma startups—from experimental promise to measurable strategic impact. Success…
Is Nabla Bio Redefining AI-Driven Protein Engineering as Pharma Seeks Faster Paths to Biologics Innovation?
Executive Summary Nabla Bio is emerging as a next-generation AI biotech focused on computationally driven protein and antibody…
Is AbCellera Biologics Building a Durable AI Antibody Discovery Engine as Pharma Partnerships Signal Multi-Billion-Dollar Potential?
Executive Summary AbCellera Biologics has established itself as a global leader in AI-driven antibody discovery, combining advanced computational…
Is Recursion Pharmaceuticals Setting the Standard for AI-Powered Drug Discovery with Strategic Deals and a $20B+ Partnership Pipeline?
Executive Summary Recursion Pharmaceuticals has emerged as a leading clinical-stage TechBio company applying artificial intelligence, automation, and large-scale…
AbbVie’s $380M North Chicago API Expansion—300 Jobs, AI Boost for Neuroscience/Obesity Pipeline
Published by BioNextAI Media – AbbVie is injecting $380 million into two new active pharmaceutical ingredient (API) facilities at…
Pfizer’s 1,200-GPU AI Blitz—$500M Bet to Slash 18-24 Month Timelines Across Pharma Value Chain
Published by BioNextAI Media – Pfizer is deploying over 1,200 NVIDIA H100/H200 GPUs in a $500-600 million infrastructure overhaul,…
